CME Radiology Grand Rounds

When: 

2nd & 4th Fridays, 12:00pm - 1:00pm

Exceptions:
5/3/24 & 5/17/24  will be the 1st & 3rd Friday of the month.
The Moskowitz Lectureship will be on the first Thursday, 11/2/23, from 5:30-6:30pm.

Where: 

Li Ka Shing Learning and Knowledge Center & Zoom.

Zoom link:
https://stanford.zoom.us/j/91767596068?pwd=aTRUVEc3K28wcHFsQ3UxUXQ5T05Hdz09


2023 - 2024 Schedule

April

Friday, April 12, 2024

12:00-1:00PM | LK120 & Zoom

Lisa Bodei, MD, PhD

Attending, Director, Targeted Radionuclide Therapy
Department of Radiology
Molecular Imaging and Therapy Service
Professor of Radiology, Weill Cornell Medical College of Cornell University
Memorial Sloan Kettering Cancer Center

Theranostics, the age of Enlightenment

Radiotheranostics are a unique type of cancer drugs which enable simultaneous imaging and therapy. Theranostics can be used to visually assess the biodistribution of the radiopharmaceutical and for the selection of patients to receive the therapeutic drug (which can be described as ‘seeing what you treat’). Thus, theranostics help reducing the risks of failure associated with drug development, by allowing the visualization and quantification of both the presence and engagement of the target. Old and recent clinical successes achieved thus far, particularly in neuroendocrine tumors and prostate cancer, go in parallel with the development of challenges associated with the effective and widespread deployment of new agents, as well as their future potential and emerging opportunities.

One of the major challenges in this field is the relatively short duration of treatment response. Several new strategies to improve the efficacy and tolerability of radiotheranostics have been proposed. Among these, the use of alpha emitters is very promising to overcome the intrinsic radioresistance of cancer cells. Also, equally important, is the individualization treatments based on the specific dosimetric estimates for the tumor and normal organs, as well as the determination of tissue radiosensitivity.

Learning objectives

On successful completion of this activity, participants should be able to describe

  1. The application of theranostics in neuroendocrine tumors and prostate cancer.
  2. The approved radiopharmaceuticals and their efficacy and tolerability profile.
  3. New strategies for the improvement of the treatment response.

Friday, April 26, 2024

12:00-1:00PM | LK130 & Zoom

Sanjeev Bhalla, MD

Section Chief, Cardiothoracic Imaging
Professor of Radiology, Cardiothoracic Imaging
Assistant Residency Program Director
Vice-Chair for Education
Mallinckrodt Institute of Radiology

Going for Broke: Imaging of Cardiothoracic Trauma

This seminar will focus on the imaging findings in cardiothoracic trauma with emphasis on a location based approach and the use of direct and indirect signs. Penetrating trauma will also be discussed.

Session Learning Objectives

  1. Highlight the concept of direct vs indirect signs in Cardiothoracic Trauma Imaging
  2. Discuss the understanding the value of points of differential deceleration
  3. Emphasize how blunt and penetrating trauma may vary in their appearances